RT Journal Article
SR Electronic
T1 Shorter treatment-naïve leukocyte telomere length is associated with poorer overall survival of patients with pancreatic ductal adenocarcinoma
JF Cancer Epidemiology Biomarkers & Prevention
JO Cancer Epidemiol Biomarkers Prev
FD American Association for Cancer Research
SP cebp.1279.2020
DO 10.1158/1055-9965.EPI-20-1279
A1 Antwi, Samuel O.
A1 Bamlet, William R.
A1 Cawthon, Richard M
A1 Rabe, Kari G.
A1 Druliner, Brooke R.
A1 Sicotte, Hugues
A1 Jatoi, Aminah
A1 Mahipal, Amit
A1 Boardman, Lisa A.
A1 Oberg, Ann L.
A1 Petersen, Gloria M.
YR 2020
UL http://cebp.aacrjournals.org/content/early/2020/11/13/1055-9965.EPI-20-1279.abstract
AB Background: Critically shortened telomeres contribute to chromosomal instability and neoplastic transformation and are associated with early death of patients with certain cancer types. Shorter leukocyte telomere length (LTL) has been associated with higher risk for pancreatic ductal adenocarcinoma (PDAC) development and might be associated also with survival of patients with PDAC. We investigated the association between treatment-naïve LTL and overall survival of patients with incident PDAC. Methods: The study included 642 consecutively enrolled PDAC patients in the Mayo Clinic Biospecimen Resource for Pancreas Research. Blood samples were obtained at the time of diagnosis, before the start of cancer treatment, from which LTL was assayed by real-time quantitative polymerase chain reaction. LTL was modeled as a continuous variable (per-interquartile range decrease in LTL) and as a categorized variable (short, medium, long). Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for overall mortality using Cox proportional hazard models. Results: Shorter treatment-naïve LTL was associated with higher mortality among PDAC patients (HRcontinuous = 1.13, 95% CI: 1.01-1.28, p-value=0.03; HRshortest vs. longest LTL = 1.29, 95% CI: 1.05-1.59, Ptrend=0.01). There was evidence of a difference in the association between LTL and overall mortality by tumor stage at diagnosis; resectable tumors (HRcontinuous = 0.91, 95% CI: 0.73-1.12), locally advanced tumors (HRcontinuous = 1.29, 95% CI: 1.07-1.56), and metastatic tumors (HRcontinuous = 1.17, 95% CI: 0.96-1.42), Pinteraction=0.04. Conclusions: Shorter treatment-naïve LTL is associated with poorer overall survival of incident PDAC patients. Impact: Peripheral blood LTL might be a prognostic marker for PDAC.